Ishiwata S, Itoh K, Yamaguchi T, Sasaki S, Ishida N, Mizugaki M
Department of Pharmaceutical Sciences, Tohoku University Hospital, Sendai, Japan.
Yakugaku Zasshi. 1995 Jul;115(7):523-7. doi: 10.1248/yakushi1947.115.7_523.
It is known that in cancer patients elevated levels of modified nucleosides originated from RNA are excreted in the urine. Modified nucleosides in the serum are thought to be more useful than those in the urine as tumor markers because they are not influenced by other factors. However the determination of these nucleosides is difficult because of their low amounts. To examine the efficacy of the modified nucleosides in the serum as tumor markers, ascites and solid tumor mouse models were prepared, and the amounts of 1-methyladenosine and pseudouridine in the serum were determined. Along with the growth of ascites tumor, the amounts of 1-methyladenosine and pseudouridine in the serum increased. The modified nucleosides in the serum in a solid tumor model also increased. This is the first report on the variation in the amount of 1-methyladenosine in the serum of tumor models, and the results suggest the usefulness of measuring the amounts of 1-methyladenosine and pseudouridine in the serum as tumor markers.
众所周知,癌症患者尿液中会排出源自RNA的修饰核苷水平升高。血清中的修饰核苷被认为比尿液中的更适合作为肿瘤标志物,因为它们不受其他因素影响。然而,由于这些核苷含量低,其测定较为困难。为了研究血清中修饰核苷作为肿瘤标志物的功效,制备了腹水和实体瘤小鼠模型,并测定了血清中1-甲基腺苷和假尿苷的含量。随着腹水肿瘤的生长,血清中1-甲基腺苷和假尿苷的含量增加。实体瘤模型血清中的修饰核苷也增加。这是关于肿瘤模型血清中1-甲基腺苷含量变化的首次报告,结果表明测定血清中1-甲基腺苷和假尿苷的含量作为肿瘤标志物是有用的。